Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
SELLAS Life Sciences Group, Inc. Common Stock
SLS
Mkt Cap
$2.01B
Volume
15.35M
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
SLS
SL
SELLAS Life Sciences Group, Inc. Common Stock
SLS
News
·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Mkt Cap
$2.02B
Volume
15.35M
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Pomerantz LLP announced investigations into securities fraud claims against SELLAS Life Sciences, JinkoSolar, and Stitch Fix. The investigation into SELLAS focuses on delayed release of phase 3 clinical trial results for Galinpepimut-S, which triggered an 13.15% stock price decline on August 28, 2026.
GlobeNewswire Inc. · Sep 29, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Pomerantz LLP is investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc. following reports that the company failed to timely release phase 3 clinical trial results for Galinpepimut-S after reaching a pre-specified trigger event (80th patient death). The stock declined 13.15% to $13.21 per share on August 28, 2026, following the news.
GlobeNewswire Inc. · Sep 8, 2026
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Benzinga · Dec 4, 2025
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
Benzinga · Jul 16, 2025
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
SELLAS presented preclinical data showing that its CDK9 inhibitor SLS009 demonstrated potent anti-proliferative activity in ASXL1 mutant colorectal cancer cell lines, suggesting its potential as a targeted therapy for this patient population.
GlobeNewswire Inc. · Jun 2, 2025
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.
GlobeNewswire Inc. · May 12, 2025
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
The article discusses recent advancements in cancer research and treatment, including promising results from clinical trials of various cancer therapies developed by companies like Oncolytics Biotech, Celcuity, Genenta Science, Sellas Life Sciences, and Amgen.
Benzinga · Feb 27, 2025
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
SELLAS Life Sciences announced that data from its Phase 2a trial of SLS009, a CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia will be presented at the 2024 ASH meeting. The trial showed promising safety and efficacy results, with a 50% response rate at the selected dose level.
GlobeNewswire Inc. · Nov 5, 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire
SELLAS Life Sciences Group, Inc. announced that the U.S. FDA has granted Rare Pediatric Disease Designation to its drug SLS009 for the treatment of pediatric acute myeloid leukemia, a serious and life-threatening disease with limited treatment options.
GlobeNewswire Inc. · Jul 16, 2024
Solaris and Warints and Yawi Communities Correct the Record of False and Misleading Claims by Anti-Mining NGOs
VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; NYSE: SLSR) (“Solaris” or the “Company”) and the Warints and Yawi Shuar communities correct the record of false and misleading claims made by anti-mining NGOs in relation to the social license for its Warintza Project (“Warintza” or “the Project”) in the province of Morona Santiago in southeastern Ecuador.
GlobeNewswire Inc. · Jul 1, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SL
SLS
SELLAS Life Sciences Group, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
SLS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SLS yet.
Related Tickers
Earnings